51.15
0.12%
-0.09
Ultragenyx Pharmaceutical Inc stock is traded at $51.15, with a volume of 569.85K.
It is down -0.12% in the last 24 hours and down -5.19% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$51.06
Open:
$50.09
24h Volume:
569.85K
Relative Volume:
0.87
Market Cap:
$4.69B
Revenue:
$481.30M
Net Income/Loss:
$-585.12M
P/E Ratio:
-5.7023
EPS:
-8.97
Net Cash Flow:
$-492.48M
1W Performance:
-3.41%
1M Performance:
-5.19%
6M Performance:
+19.29%
1Y Performance:
+31.34%
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Jun-14-23 | Resumed | Credit Suisse | Outperform |
Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-18-23 | Resumed | Canaccord Genuity | Buy |
Dec-30-22 | Resumed | H.C. Wainwright | Buy |
Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-30-21 | Initiated | H.C. Wainwright | Buy |
Aug-19-21 | Initiated | UBS | Sell |
Jul-15-21 | Initiated | Guggenheim | Neutral |
Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
Jun-04-21 | Resumed | Robert W. Baird | Neutral |
May-06-21 | Upgrade | Citigroup | Neutral → Buy |
May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
Apr-26-21 | Resumed | Credit Suisse | Neutral |
Mar-02-21 | Resumed | Stifel | Buy |
Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
Nov-24-20 | Resumed | Evercore ISI | In-line |
Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
Aug-02-19 | Resumed | Wedbush | Outperform |
Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Feb-22-19 | Resumed | Raymond James | Outperform |
Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
May-10-18 | Initiated | Goldman | Neutral |
Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
Mar-22-18 | Resumed | Piper Jaffray | Overweight |
Feb-21-18 | Reiterated | Stifel | Buy |
Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
Jan-18-18 | Initiated | Credit Suisse | Outperform |
Dec-05-17 | Reiterated | Barclays | Equal Weight |
Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Wealth Enhancement Advisory Services LLC Purchases 14,394 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast - Benzinga
Trend Tracker for (RARE) - Stock Traders Daily
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Emerald Mutual Fund Advisers Trust - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Trimmed by abrdn plc - MarketBeat
RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? - Yahoo Finance
Oversold Conditions For Ultragenyx Pharmaceutical (RARE) - Nasdaq
10,904 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bought by Pallas Capital Advisors LLC - MarketBeat
Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday - MarketBeat
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update - GlobeNewswire
Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $85.08 - MarketBeat
How To Trade (RARE) - Stock Traders Daily
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year - Yahoo Finance
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance
Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical - Benzinga
TD Cowen Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $73.00 - MarketBeat
Ultragenyx Pharmaceutical's (NASDAQ:RARE) investors will be pleased with their favorable 70% return over the last year - Simply Wall St
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Cwm LLC Buys 21,111 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Sees Significant Decline in Short Interest - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Sells $393,853.40 in Stock - MarketBeat
Ultragenyx CFO sells shares worth over $390k By Investing.com - Investing.com South Africa
Ultragenyx CFO sells shares worth over $390k - Investing.com
RARE's Wilson Disease Candidate Betters Standard Therapy in Study - MSN
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag - MSN
Osteogenesis Imperfecta Treatment Market: Global Type, - openPR
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MSN
Squarepoint Ops LLC Trims Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx gains FDA breakthrough status for OI drug - Investing.com
FDA grants breakthrough therapy status to Ultragenyx's osteogenesis imperfecta drug - Investing.com
Ultragenyx gains FDA breakthrough status for OI drug By Investing.com - Investing.com South Africa
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta - The Manila Times
Ultragenyx Pharmaceutical's Bone Disease Drug Gets FDA's Breakthrough Therapy Designation - MarketWatch
AQR Capital Management LLC Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx stock rated Outperform as analyst sees $900M peak sales potential - Investing.com
RARE's Wilson Disease Candidate Betters Standard Therapy In Study - Barchart
Ultragenyx tweaks gene therapy dosing to dial up efficacy after seeing signs of activity - Fierce Biotech
The Manufacturers Life Insurance Company Cuts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ultragenyx Pharmaceutical Inc Stock (RARE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
KAKKIS EMIL D | President & CEO |
Sep 03 '24 |
Sale |
55.85 |
20,000 |
1,117,000 |
2,223,985 |
Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Sep 03 '24 |
Sale |
56.19 |
91 |
5,113 |
41,551 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):